Equities

Krystal Biotech Inc

Krystal Biotech Inc

Actions
  • Price (EUR)174.35
  • Today's Change5.30 / 3.14%
  • Shares traded95.00
  • 1 Year change+88.49%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments532379438
Total Receivables, Net42----
Total Inventory6.99----
Prepaid expenses6.714.614.17
Other current assets, total------
Total current assets588384442
Property, plant & equipment, net168170120
Goodwill, net------
Intangibles, net------
Long term investments624.6264
Note receivable - long term------
Other long term assets0.260.320.07
Total assets818558626
LIABILITIES
Accounts payable4.133.988.40
Accrued expenses242517
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total4.490.310.17
Total current liabilities332926
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total6.627.376.98
Total liabilities403633
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital1,048804735
Retained earnings (accumulated deficit)(270)(281)(141)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.64(0.73)(0.16)
Total equity779522594
Total liabilities & shareholders' equity818558626
Total common shares outstanding282625
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.